Stockwatch: BioMarin's Biggest Liabilities
This article was originally published in Scrip
In an amalgamation of human resources jargon and accounting-speak, many companies describe their employees as their 'greatest asset'. In a similar but inverse metaphor, when many investors think of risk, they only think of the potential to lose money, rather than the chances of making excess positive returns. Despite losing only 13.6% of its value in the past two weeks (over which time admittedly the NASDAQ Biotech Index gained 4.5%), BioMarin Pharmaceutical, Inc. has demonstrated that a company's employees can also be its biggest liability.
You may also be interested in...
Biogen’s poor third-quarter results cannot be blamed solely on the pandemic. Pipeline attrition and underperformance in most franchises pushes all the risk onto a dubious throw of the regulatory dice.
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.